Madrigal Pharmaceuticals to Release Second-Quarter 2026 Financial Results and Host Webcast on July 30, 2026

Madrigal Pharmaceuticals (Nasdaq: MDGL) plans to release its second-quarter 2026 financial results on Thursday, July 30, 2026, before the U.S. market opens.

Rhea-AI Summary

Madrigal Pharmaceuticals (Nasdaq: MDGL) plans to release its second-quarter 2026 financial results on Thursday, July 30, 2026, before the U.S. market opens. Management will host a live webcast at 8:00 a.m. Eastern Time, accessible via the company’s Investor Relations website, with a replay available about two hours later.

Argus Jul 16 session

-0.86% close to close Open Argus

Details

News Market Reaction – MDGL

In the Jul 16 session, MDGL declined 0.86%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This earnings-date notice sits against a backdrop of historically small average moves of 0.45% aroun...

Analysis

This earnings-date notice sits against a backdrop of historically small average moves of 0.45% around similar announcements, moderate short positioning, and recent insider net selling. Investors may watch whether the upcoming results meaningfully change that muted historical reaction pattern.

Key Figures

Earnings release date: July 30, 2026 Webcast time: 8 a.m. Eastern Time Pre-registration lead time: 15 minutes +1 more

Earnings release date

July 30, 2026

Second-quarter 2026 financial results release

Webcast time

8 a.m. Eastern Time

Management webcast to review Q2 2026 results

Pre-registration lead time

15 minutes

Recommended registration time before webcast start

Replay availability delay

2 hours

Approximate time after live webcast for replay posting

Previous Earnings date Reports

2 past events · Latest: Apr 22

Same Type 2 events

1. Apr 22

   Earnings date notice

   24h Move

   +0.8%

   Scheduled Q1 2026 results release and webcast before market open.

2. Feb 02

   Earnings date notice

   24h Move

   +0.1%

   Announced Q4 and full-year 2025 results date and accompanying webcast.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CONSHOHOCKEN, Pa., July 16, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its second-quarter 2026 financial results on Thursday, July 30, 2026, prior to the open of the U.S. financial markets.

Following the announcement, Madrigal’s management will host a live webcast at 8 a.m. Eastern Time to review the Company’s financial and operating results.

The live webcast may be accessed at the Investor Relations section of the Madrigal Pharmaceuticals website. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast.

The webcast will be available approximately two hours after the live webcast.

About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra was the first medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). For more information, visit www.madrigalpharma.com.

Investor Contact
Tina Ventura, Madrigal Pharmaceuticals, Inc., IR@madrigalpharma.com

Media Contact
Christopher Frates, Madrigal Pharmaceuticals, Inc., media@madrigalpharma.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Madrigal Pharmaceuticals (MDGL) report its Q2 2026 financial results?

Madrigal Pharmaceuticals will report its Q2 2026 financial results on Thursday, July 30, 2026, before U.S. markets open. According to Madrigal Pharmaceuticals, the release will precede a management webcast later that morning to review financial and operating results in more detail.

What time is the Madrigal Pharmaceuticals (MDGL) Q2 2026 earnings webcast on July 30, 2026?

The Madrigal Pharmaceuticals Q2 2026 webcast is scheduled for 8:00 a.m. Eastern Time on July 30, 2026. According to Madrigal Pharmaceuticals, management will review the company’s financial and operating results during this live online event for investors and other interested parties.

How can investors access the Madrigal Pharmaceuticals (MDGL) Q2 2026 financial results webcast?

Investors can access the Madrigal Pharmaceuticals Q2 2026 webcast through the Investor Relations section of the company’s website. According to Madrigal Pharmaceuticals, participants are encouraged to register at least 15 minutes before the scheduled 8:00 a.m. Eastern Time start for a timely connection.

Will a replay of the Madrigal Pharmaceuticals (MDGL) Q2 2026 webcast be available?

Yes, a replay of the Madrigal Pharmaceuticals Q2 2026 webcast will be available. According to Madrigal Pharmaceuticals, the webcast will be accessible approximately two hours after the live event, via the Investor Relations section of the company’s website for later listening.

Where will Madrigal Pharmaceuticals (MDGL) publish its Q2 2026 earnings details for investors?

Madrigal Pharmaceuticals will publish Q2 2026 earnings details in a financial results release on July 30, 2026. According to Madrigal Pharmaceuticals, additional commentary will be provided during the same day’s webcast, accessible through the company’s Investor Relations website for investors and analysts.